Full Press Release Details
ifrs-full:IssuedCapitalMember
ifrs-full:OtherEquityInterestMember
ifrs-full:RetainedEarningsMember
ifrs-full:AccumulatedOtherComprehensiveIncomeMember
ifrs-full:IssuedCapitalMember
ifrs-full:OtherEquityInterestMember
ifrs-full:RetainedEarningsMember
ifrs-full:AccumulatedOtherComprehensiveIncomeMember
ifrs-full:IssuedCapitalMember
ifrs-full:OtherEquityInterestMember
ifrs-full:RetainedEarningsMember
ifrs-full:AccumulatedOtherComprehensiveIncomeMember
ifrs-full:IssuedCapitalMember
ifrs-full:OtherEquityInterestMember
ifrs-full:RetainedEarningsMember
ifrs-full:AccumulatedOtherComprehensiveIncomeMember
ifrs-full:IssuedCapitalMember
ifrs-full:OtherEquityInterestMember
ifrs-full:RetainedEarningsMember
ifrs-full:AccumulatedOtherComprehensiveIncomeMember
ifrs-full:IssuedCapitalMember
ifrs-full:OtherEquityInterestMember
ifrs-full:RetainedEarningsMember
ifrs-full:AccumulatedOtherComprehensiveIncomeMember
AEZS:LicenseFeesMember
AEZS:LicenseFeesMember
AEZS:DevelopmentServicesMember
AEZS:DevelopmentServicesMember
AEZS:ProductSalesMember
AEZS:ProductSalesMember
AEZS:RoyaltiesMember
AEZS:RoyaltiesMember
AEZS:SupplyChainMember
AEZS:SupplyChainMember
AEZS:UnsatisfiedPerformanceObligationsMember
AEZS:IndicationPerformanceObligationMember
AEZS:PediatricIndicationPerformanceMember
AEZS:NovoAmendmentMember
AEZS:PharmanoviaLicenseAgreementMember
AEZS:NKLicenseAgreementMember
AEZS:NovoAmendmentMember
AEZS:ConsilientHealthMember
AEZS:NKLicenseAgreementMember
ifrs-full:PensionDefinedBenefitPlansMember
AEZS:OtherBenefitPlansMember
ifrs-full:PensionDefinedBenefitPlansMember
AEZS:OtherBenefitPlansMember
ifrs-full:PensionDefinedBenefitPlansMember
AEZS:OtherBenefitPlansMember
AEZS:ShareholdersAndBoardOfDirectorsMember
AEZS:DeferredStockUnitsMember
AEZS:TwoThousandEighteenLongTermIncentivePlanMember
AEZS:TwoThousandEighteenLongTermIncentivePlanMember
AEZS:EmployeeStockOption1DeferredStockUnitsMember
AEZS:EmployeeStockOption1DeferredStockUnitsMember
AEZS:LessThanOneYearMember
AEZS:OneToThreeYearsMember
AEZS:FourToFiveYearsMember
AEZS:MoreThanFiveYearsMember
ifrs-full:TopOfRangeMember
Aeterna Zentaris Inc.
Condensed Interim Consolidated Financial Statements
As of March 31, 2023, and for the three
months ended March 31, 2023 and 2022
(In thousands of US dollars)
| Condensed Interim Consolidated Statements of Financial Position | 2 |
| Condensed Interim Consolidated Statements of Changes in Shareholders' Equity | 3 |
| Condensed Interim Consolidated Statements of Loss and Comprehensive Loss | 4 |
| Condensed Interim Consolidated Statements of Cash Flows | 5 |
| Notes to Condensed Interim Consolidated Financial Statements | 6 |
Interim Consolidated Statements of Financial Position
thousands of US dollars)
| As of March 31, 2023 | As of December 31, 2022 | |||||||
| $ | $ | |||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | 46,560 | 50,611 | ||||||
| Trade and other receivables | 557 | 732 | ||||||
| Inventory | 227 | 229 | ||||||
| Income taxes receivable | 1,450 | 1,428 | ||||||
| Prepaid expenses and other current assets | 1,914 | 2,488 | ||||||
| Total current assets | 50,708 | 55,488 | ||||||
| Non-current assets | ||||||||
| Restricted cash equivalents | 326 | 322 | ||||||
| Property and equipment | 248 | 216 | ||||||
| Total non-current assets | 574 | 538 | ||||||
| Total assets | 51,282 | 56,026 | ||||||
| LIABILITIES | ||||||||
| Current liabilities | ||||||||
| Payables and accrued liabilities | 4,130 | 3,828 | ||||||
| Provisions | 44 | 45 | ||||||
| Income taxes payable | 109 | 108 | ||||||
| Deferred revenues (note 3) | 2,017 | 2,949 | ||||||
| Lease liabilities | 134 | 114 | ||||||
| Total current liabilities | 6,434 | 7,044 | ||||||
| Non-current liabilities | ||||||||
| Deferred revenues (note 3) | 1,777 | 1,684 | ||||||
| Deferred gain | 111 | 110 | ||||||
| Lease liabilities | 76 | 65 | ||||||
| Employee future benefits (note 4) | 11,498 | 11,159 | ||||||
| Provisions | 178 | 188 | ||||||
| Total non-current liabilities | 13,640 | 13,206 | ||||||
| Total liabilities | 20,074 | 20,250 | ||||||
| Shareholders' equity | ||||||||
| Share capital (note 5) | 293,410 | 293,410 | ||||||
| Warrants | 5,085 | 5,085 | ||||||
| Other capital | 90,349 | 90,332 | ||||||
| Deficit | ( 356,501 | ) | ( 352,084 | ) | ||||
| Accumulated other comprehensive loss | ( 1,135 | ) | ( 967 | ) | ||||
| Total Shareholders' equity | 31,208 | 35,776 | ||||||
| Total liabilities and shareholders' equity | 51,282 | 56,026 |
accompanying notes are an integral part of these condensed interim consolidated financial statements.
by the Board of Directors
| /s/ Carolyn Egbert | /s/ Dennis Turpin | |
| Carolyn Egbert, Chair of the Board | Dennis Turpin, Director |
Interim Consolidated Statements of Changes in Shareholders' Equity
the three months ended March 31, 2023 and 2022
thousands of US dollars)
| Share capital | Warrants | Other capital | Deficit | Accumulated other comprehensive loss | Total | |||||||||||||||||||
| $ | $ | $ | $ | $ | $ | |||||||||||||||||||
| Balance - January 1, 2023 | 293,410 | 5,085 | 90,332 | ( 352,084 | ) | ( 967 | ) | 35,776 | ||||||||||||||||
| Net loss | - | - | - | ( 4,255 | ) | - | ( 4,255 | ) | ||||||||||||||||
| Other comprehensive loss: | ||||||||||||||||||||||||
| Foreign currency translation adjustments | - | - | - | - | ( 168 | ) | ( 168 | ) | ||||||||||||||||
| Actuarial loss on defined benefit plans and remeasurement of the net defined benefit liability (note 4) | - | - | - | ( 162 | ) | - | ( 162 | ) | ||||||||||||||||
| Comprehensive loss | - | - | - | ( 4,417 | ) | ( 168 | ) | ( 4,585 | ) | |||||||||||||||
| Share-based compensation costs (note 5) | - | - | 17 | - | - | 17 | ||||||||||||||||||
| Balance - March 31, 2023 | 293,410 | 5,085 | 90,349 | ( 356,501 | ) | ( 1,135 | ) | 31,208 |
| Share capital | Warrants | Other capital | Deficit | Accumulated other comprehensive loss | Total | |||||||||||||||||||
| $ | $ | $ | $ | $ | $ | |||||||||||||||||||
| Balance - January 1, 2022 | 293,410 | 5,085 | 89,788 | ( 334,619 | ) | ( 678 | ) | 52,986 | ||||||||||||||||
| Balance - Value | 293,410 | 5,085 | 89,788 | ( 334,619 | ) | ( 678 | ) | 52,986 | ||||||||||||||||
| Net loss | - | - | - | ( 2,640 | ) | - | ( 2,640 | ) | ||||||||||||||||
| Other comprehensive loss: | ||||||||||||||||||||||||
| Foreign currency translation adjustments | - | - | - | - | 37 | 37 | ||||||||||||||||||
| Actuarial gain on defined benefit plans and remeasurement of the net defined benefit liability | - | - | - | 2,749 | - | 2,749 | ||||||||||||||||||
| Comprehensive income | - | - | - | 109 | 37 | 146 | ||||||||||||||||||
| Comprehensive income (loss) | - | - | - | 109 | 37 | 146 | ||||||||||||||||||
| Share-based compensation costs (note 5) | - | - | 27 | - | - | 27 | ||||||||||||||||||
| Balance - March 31, 2022 | 293,410 | 5,085 | 89,815 | ( 334,510 | ) | ( 641 | ) | 53,159 | ||||||||||||||||
| Balance - Value | 293,410 | 5,085 | 89,815 | ( 334,510 | ) | ( 641 | ) | 53,159 |
accompanying notes are an integral part of these condensed interim consolidated financial statements.
Interim Consolidated Statements of Loss and Comprehensive Loss
the three months ended March 31, 2023 and 2022
thousands of US dollars, except share and per share data)
| Three months ended | ||||||||
| March 31, | ||||||||
| 2023 | 2022 | |||||||
| $ | $ | |||||||
| Revenues (note 3) | 2,128 | 1,517 | ||||||
| Expenses | ||||||||
| Cost of sales | 17 | 79 | ||||||
| Research and development | 4,012 | 2,390 | ||||||
| Selling, general and administrative | 2,306 | 1,861 | ||||||
| Total expenses | 6,335 | 4,330 | ||||||
| Loss from operations | ( 4,207 | ) | ( 2,813 | ) | ||||
| Gain (loss) due to changes in foreign currency exchange rates | ( 59 | ) | 174 | |||||
| Other finance (costs) income | 11 | ( 1 | ) | |||||
| Net finance (costs) income | ( 48 | ) | 173 | |||||
| Loss before income taxes | ( 4,255 | ) | ( 2,640 | ) | ||||
| Income tax recovery | - | - | ||||||
| Net loss | ( 4,255 | ) | ( 2,640 | ) | ||||
| Other comprehensive loss: | ||||||||
| Items that may be reclassified subsequently to profit or loss: | ||||||||
| Foreign currency translation adjustments | ( 168 | ) | 37 | |||||
| Items that will not be reclassified to profit or loss: | ||||||||
| Actuarial gain (loss) on defined benefit plans and remeasurement of the net defined benefit liability (note 4) | ( 162 | ) | 2,749 | |||||
| Comprehensive loss | ( 4,585 | ) | 146 | |||||
| Basic and diluted loss per share (note 7) | ( 0.88 | ) | ( 0.54 | ) | ||||
| Weighted average number of shares outstanding (basic and diluted) | 4,855,876 | 4,855,876 |
accompanying notes are an integral part of these condensed interim consolidated financial statements.
Interim Consolidated Statements of Cash Flows
the three months ended March 31, 2023 and 2022
thousands of US dollars)
| $ | $ | |||||||
| Three months ended | ||||||||
| March 31, | ||||||||
| 2023 | 2022 | |||||||
| $ | $ | |||||||
| Cash flows from operating activities | ||||||||
| Net loss for the period | ( 4,255 | ) | ( 2,640 | ) | ||||
| Items not affecting cash and cash equivalents: | ||||||||
| Provision | ( 8 | ) | ( 2 | ) | ||||
| Depreciation and amortization | 40 | 36 | ||||||
| Share-based compensation costs | 17 | 27 | ||||||
| Employee future benefits | 135 | 99 | ||||||
| Amortization of deferred revenues | ( 760 | ) | ( 828 | ) | ||||
| Net foreign exchange differences | 8 | ( 174 | ) | |||||
| Other non-cash items | 1 | 14 | ||||||
| Refund of income taxes | - | 881 | ||||||
| Changes in operating assets and liabilities (note 6) | 761 | 1,126 | ||||||
| Net cash used in operating activities | ( 4,061 | ) | ( 1,461 | ) | ||||
| Cash flows from financing activities | ||||||||
| Payments on lease liabilities | ( 38 | ) | ( 34 | ) | ||||
| Net cash used in financing activities | ( 38 | ) | ( 34 | ) | ||||
| Cash flows from investing activities | ||||||||
| Purchase of property and equipment | ( 2 | ) | ( 6 | ) | ||||
| Net cash used in investing activities | ( 2 | ) | ( 6 | ) | ||||
| Effect of exchange rate changes on cash and cash equivalents | 50 | ( 203 | ) | |||||
| Net change in cash and cash equivalents | ( 4,051 | ) | ( 1,704 | ) | ||||
| Cash and cash equivalents - Beginning of period | 50,611 | 65,300 | ||||||
| Cash and cash equivalents - End of period | 46,560 | 63,596 |
accompanying notes are an integral part of these condensed interim consolidated financial statements.
to the Condensed Interim Consolidated Financial Statements
of March 31, 2023, and for the three months ended March 31, 2023 and 2022
thousands of US dollars, except share and per share data and as otherwise noted)
1. Business overview
Zentaris (the "Company" or "Aeterna") is a specialty biopharmaceutical company commercializing and developing
therapeutics and diagnostic tests. The Company's lead product, Macrilen (macimorelin), is the first and only U.S.
Food and Drug Administration ("FDA") and European Medicines Agency-approved oral test indicated for the diagnosis of patients
with adult growth hormone deficiency ("AGHD"). Macrilen is currently marketed in the US through a license
agreement (the "Novo Amendment") between the Company and Novo Nordisk Health Care AG ("Novo") until May 2023
and in the United Kingdom and Europe through a license agreement with Atnahs Pharma UK Limited ("Pharmanovia") under the
trade name of Ghryvelin . The Company is also dedicated to the development of therapeutic assets and has taken steps to establish
a pre-clinical pipeline to potentially address unmet medical needs across several indications with a focus on rare or orphan indications.